Neoprobe (NEOP) jumps 4.5% AH after announcing it has licensed worldwide exclusive rights to...
Neoprobe (NEOP) jumps 4.5% AH after announcing it has licensed worldwide exclusive rights to AstraZenaca's (AZN) AZD4694 patient imaging solution, and plans to initiate Phase III trials in early 2013. Neoprobe will pay AstraZanaca a $5M up-front licensing fee, as well as future milestone payments and royalties.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs